| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
15002134094 |
| Email: |
marketing@targetmol.cn |
| Products Intro: |
Product Name:NR2F1 agonist 1
CAS:374101-64-1
Package:50mg/RMB 15300;100mg/RMB 19500;25mg/RMB 11700
|
| Company Name: |
Biorbyt Ltd.
|
| Tel: |
+44 (0)1223 859 353 |
| Email: |
info@biorbyt.com |
| Products Intro: |
Product Name:NR2F1 agonist 1
CAS:374101-64-1
|
| Company Name: |
Interbioscreen Ltd.
|
| Tel: |
+7 (49) 6524-0091 |
| Email: |
screen@ibscreen.chg.ru |
| Products Intro: |
CAS:374101-64-1
Purity:92% Package:1mg Remarks:C28H30N4OS
|
| Company Name: |
PHARMEKS Ltd.
|
| Tel: |
+7 (495) 702-9648 |
| Email: |
sales@pharmeks.com |
| Products Intro: |
CAS:374101-64-1
Package:5μmol Remarks:C28H30N4OS
|
1-(ethylthio)-4-phenethyl-4H-spiro[benzo[h][1,2,4]triazolo[4,3-a]quinazoline-6,1'-cyclohexan]-5(7H)-one manufacturers
- NR2F1 agonist 1
-
- $2180.00 / 50mg
-
2025-04-30
- CAS:374101-64-1
- Min. Order:
- Purity:
- Supply Ability: 10g
|
| | 1-(ethylthio)-4-phenethyl-4H-spiro[benzo[h][1,2,4]triazolo[4,3-a]quinazoline-6,1'-cyclohexan]-5(7H)-one Basic information |
| Product Name: | 1-(ethylthio)-4-phenethyl-4H-spiro[benzo[h][1,2,4]triazolo[4,3-a]quinazoline-6,1'-cyclohexan]-5(7H)-one | | Synonyms: | 1-(ethylthio)-4-phenethyl-4H-spiro[benzo[h][1,2,4]triazolo[4,3-a]quinazoline-6,1'-cyclohexan]-5(7H)-one;Spiro[benzo[h][1,2,4]triazolo[4,3-a]quinazoline-6(4H),1'-cyclohexan]-5(7H)-one, 1-(ethylthio)-4-(2-phenylethyl)-;NR2F1 agonist 1 | | CAS: | 374101-64-1 | | MF: | C28H30N4OS | | MW: | 470.63 | | EINECS: | | | Product Categories: | | | Mol File: | 374101-64-1.mol | ![1-(ethylthio)-4-phenethyl-4H-spiro[benzo[h][1,2,4]triazolo[4,3-a]quinazoline-6,1'-cyclohexan]-5(7H)-one Structure](CAS/20180703/GIF/374101-64-1.gif) |
| | 1-(ethylthio)-4-phenethyl-4H-spiro[benzo[h][1,2,4]triazolo[4,3-a]quinazoline-6,1'-cyclohexan]-5(7H)-one Chemical Properties |
| Boiling point | 719.9±70.0 °C(Predicted) | | density | 1.31±0.1 g/cm3(Predicted) | | pka | 1.47±0.20(Predicted) | | form | Solid | | color | Off-white to light yellow |
| | 1-(ethylthio)-4-phenethyl-4H-spiro[benzo[h][1,2,4]triazolo[4,3-a]quinazoline-6,1'-cyclohexan]-5(7H)-one Usage And Synthesis |
| Uses | NR2F1 agonist 1, a nuclear receptor NR2F1 agonist, specifically activates dormancy programs in malignant cells. NR2F1 agonist 1 up-regulates NR2F1 and downstream target genes that regulate dormancy. NR2F1 agonist 1 induces neural crest-like and growth suppression in head and neck squamous cell carcinoma (HNSCC) via NR2F1 activation. NR2F1 agonist 1 inhibits tumor growth in a mouse primary tumor model[1]. | | in vivo | NR2F1 agonist 1 (0.5 mg/kg/day; i.p.; 3 weeks) inhibits inhibits primary tumor growth and metastatic growth in lungs in mouse models[1].
| Animal Model: | BALB/c nu/nu mice bearing GFP-tagged T-HEp3 PDX cells[1] | | Dosage: | 0.5 mg/kg/day | | Administration: | Intraperitoneal injection; injected for 3 weeks or for 1 week followed by DMSO for 2 weeks | | Result: | Did not induce apoptosis of proliferating primary tumor cells, but exhibited metastasis inhibitory effect against T-HEp3 cells. |
| | References | [1] Khalil BD, et al. An NR2F1-specific agonist suppresses metastasis by inducing cancer cell dormancy. J Exp Med. 2022 Jan 3;219(1):e20210836. DOI:10.1084/jem.20210836 |
| | 1-(ethylthio)-4-phenethyl-4H-spiro[benzo[h][1,2,4]triazolo[4,3-a]quinazoline-6,1'-cyclohexan]-5(7H)-one Preparation Products And Raw materials |
|